News & Updates

Show Multimedia Only

Glucose level affects immunotherapy efficacy in NSCLC

02 Apr 2026 by

A study from Israel presented at ELCC 2026 supports the role of glucose control as a modifiable host factor that could improve the effectiveness of immune checkpoint inhibitors in the treatment of non-small cell lung cancer (NSCLC).

Glucose level affects immunotherapy efficacy in NSCLC

02 Apr 2026

Mycophenolate mofetil as good as methotrexate for juvenile localized scleroderma

02 Apr 2026

In the treatment of patients with juvenile localized scleroderma, mycophenolate mofetil compares favourably with methotrexate in terms of reducing clinical activity and flare rate, according to a retrospective study.

Mycophenolate mofetil as good as methotrexate for juvenile localized scleroderma

02 Apr 2026

First-line panitumumab improves metastatic-site resection rates in RAS wild-type mCRC

02 Apr 2026

At the European Society for Medical Oncology (ESMO) Asia Congress 2025 in Singapore, results of a retrospective cohort study that evaluated first-line panitumumab- vs cetuximab-based therapy in patients with newly diagnosed RAS wild-type metastatic colorectal cancer (mCRC) were reported. The analysis focused on overall survival (OS) and metastatic-site resection rates, providing valuable real-world insights into treatment selection beyond traditional survival endpoints.

First-line panitumumab improves metastatic-site resection rates in RAS wild-type mCRC

02 Apr 2026

Pimicotinib for tenosynovial giant cell tumour hits targets in pivotal trial

01 Apr 2026 by

The highly selective colony-stimulating factor-1 receptor inhibitor pimicotinib demonstrates robust antitumour activity in patients with tenosynovial giant cell tumour, yielding meaningful improvements in physical function and symptom burden with a manageable safety profile, according to the international phase III MANEUVER trial.

Pimicotinib for tenosynovial giant cell tumour hits targets in pivotal trial

01 Apr 2026

GLP-1 RAs lower risk of liver-related outcomes, death in patients with harmful alcohol use

01 Apr 2026

Using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of liver outcomes, death, and harmful alcohol use in patients with alcohol use disorder, reveals a study.

GLP-1 RAs lower risk of liver-related outcomes, death in patients with harmful alcohol use

01 Apr 2026

One-time screening in never-smokers a game-changer in lung cancer

01 Apr 2026 by

Data from a large, prospective, non-randomized study in China show that one-time low-dose computed tomography (LDCT) screening is associated with a significant reduction in lung cancer mortality in a non–risk-based population, including those who have never smoked.

One-time screening in never-smokers a game-changer in lung cancer

01 Apr 2026

Preworkout dietary supplement use in young people linked to shorter sleep

01 Apr 2026

Adolescents and young adults who use preworkout dietary supplements are sleeping an average of not more than 5 h every night, as shown in a study.

Preworkout dietary supplement use in young people linked to shorter sleep

01 Apr 2026

GLP-1RAs may offer histologic benefits in adults with MASH

01 Apr 2026 by

Among adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH), treatment with glucagon-like peptide 1 receptor agonists (GLP-1RAs), particularly semaglutide or liraglutide, is associated with higher rates of MASH resolution without worsening of fibrosis compared with placebo, according to a recent Singapore study.

GLP-1RAs may offer histologic benefits in adults with MASH

01 Apr 2026

Real-world data reaffirm RSVpreF vaccine’s benefit in older individuals

31 Mar 2026

Along with its efficacy established in the pivotal RENOIR trial, real-world studies published more recently continue to demonstrate effectiveness of the bivalent respiratory syncytial virus (RSV) prefusion F protein–based (RSVpreF) vaccine in protecting against RSV-associated outcomes in older individuals aged ≥60 years.

Real-world data reaffirm RSVpreF vaccine’s benefit in older individuals

31 Mar 2026

BP-lowering via RAAS inhibition delivers better outcomes in paediatric CKD

31 Mar 2026 by

In the management of hypertension in paediatric chronic kidney disease (CKD), renin-angiotensin-aldosterone system inhibition (RAASi) is associated with better kidney function preservation and blood pressure control compared with calcium channel blockade, according to a real-world comparative-effectiveness study.

BP-lowering via RAAS inhibition delivers better outcomes in paediatric CKD

31 Mar 2026

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

Glucose level affects immunotherapy efficacy in NSCLC

Glucose level affects immunotherapy efficacy in NSCLC

Mycophenolate mofetil as good as methotrexate for juvenile localized scleroderma

Mycophenolate mofetil as good as methotrexate for juvenile localized scleroderma

First-line panitumumab improves metastatic-site resection rates in RAS wild-type mCRC

First-line panitumumab improves metastatic-site resection rates in RAS wild-type mCRC

Pimicotinib for tenosynovial giant cell tumour hits targets in pivotal trial

Pimicotinib for tenosynovial giant cell tumour hits targets in pivotal trial

GLP-1 RAs lower risk of liver-related outcomes, death in patients with harmful alcohol use

GLP-1 RAs lower risk of liver-related outcomes, death in patients with harmful alcohol use

One-time screening in never-smokers a game-changer in lung cancer

One-time screening in never-smokers a game-changer in lung cancer

Preworkout dietary supplement use in young people linked to shorter sleep

Preworkout dietary supplement use in young people linked to shorter sleep

GLP-1RAs may offer histologic benefits in adults with MASH

GLP-1RAs may offer histologic benefits in adults with MASH

Real-world data reaffirm RSVpreF vaccine’s benefit in older individuals

Real-world data reaffirm RSVpreF vaccine’s benefit in older individuals

BP-lowering via RAAS inhibition delivers better outcomes in paediatric CKD

BP-lowering via RAAS inhibition delivers better outcomes in paediatric CKD